Updates on drug discovery in ovarian cancerReport as inadecuate

Updates on drug discovery in ovarian cancer - Download this document for free, or read online. Document in PDF available to download.

Gynecologic Oncology Research and Practice

, 1:3

First Online: 30 September 2014Received: 20 March 2014Accepted: 04 August 2014DOI: 10.1186-2053-6844-1-3

Cite this article as: Gibson, S.J., Tewari, K.S., Monk, B.J. et al. gynaecol oncol res pract 2014 1: 3. doi:10.1186-2053-6844-1-3


Drug discovery in the ovarian cancer arena continues to launch important new clinical trials. Many biologic agents are being studied in phase II and phase III clinical trials for recurrent disease. These agents include compounds that disrupt angiogenesis through a variety of mechanisms. Other oncogenic pathways are also specifically targeted such as PARP, MEK, and topoisomerase inhibitors which are currently being studied in phase III trials. Various cytotoxic agents, as well as therapeutic vaccines, are also under investigation, and continue to demonstrate promising new data. The relevant agents in the treatment of ovarian cancer which have demonstrated positive phase II activity will be discussed.

KeywordsOvarian cancer Chemotherapy Targeted therapy Angiogenesis Recurrent cancer Clinical trials Electronic supplementary materialThe online version of this article doi:10.1186-2053-6844-1-3 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Author: Steven J Gibson - Krishnansu S Tewari - Bradley J Monk - Dana M Chase

Source: https://link.springer.com/

Related documents